This whitepaper discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models and emphasises the importance of accurate dose prediction to ensure patient safety and trial success. 

In this whitepaper you will learn about:

• The significance of selecting appropriate starting doses in clinical trials.
• Utilising humanised mouse models to mimic human responses.
• Integration of preclinical data and physiological parameters for dose prediction.
• Advantages of refining dosing strategies, minimising risks, and improving trial outcomes.
• Enhancing understanding of drug behaviour, toxicity, and efficacy in humans.
• The potential to revolutionise drug development by optimising dose selection.

Brought to you by